Poolbeg Pharma PLC

Equities

POLB

GB00BKPG7Z60

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:14 2024-05-31 EDT			5-day change	1st Jan Change
13.7 ^GBX	+4.58%		+4.58%	+51.38%

05-01	Poolbeg Pharma Secures Full Patent in US for Immunomodulator II	MT
05-01	Poolbeg Pharma celebrates full patent approval for Immunomodulator II	AN

Poolbeg Pharma and CytoReason identify "very exciting influenza targets"

June 29, 2023 at 03:56 am

(via NewsDirect)

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant breakthrough" in their world-first influenza Artificial Intelligence ('AI') Programme. Skillington says that the collaboration has yielded some "very exciting influenza targets" and that Poolbeg will now be "actively exploring the most effective way to bring them forward into development." He also highlights Poolbeg's RSV-focused AI collaboration with CytoReason that concluded in 2022, saying that Poolbeg "is now working on validating those targets... and will have data before the end of the year."

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about Poolbeg Pharma PLC

Poolbeg Pharma Secures Full Patent in US for Immunomodulator II	05-01	MT
Poolbeg Pharma celebrates full patent approval for Immunomodulator II	05-01	AN
Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application	05-01	CI
Poolbeg Pharma Signs Option Deal to Buy Orphan Drug Candidate from Silk Road Therapeutics	04-30	MT
EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down	04-30	AN
Earnings Flash (POLB.L) POOLBEG PHARMA Posts FY23 Loss GBX-0.79	04-30	MT
EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake	03-20	AN
Poolbeg Pharma plc Announces POLB 001 US Patent Update	03-20	CI
Diversified Energy offers dividend alternative	02-15	AN
Poolbeg Pharma's Nonexecutive Chair Transitions to Executive Role	02-15	MT
Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman	02-15	CI
Katoro Gold launches fundraising, eyes board shake-up	02-12	AN
Independent Research Confirms >$10 Billion Market Opportunity for POLB 001 as A Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome	02-12	CI
Poolbeg Pharma Therapy Shows Efficacy in Lowering Cancer Immunotherapy-induced Cytokine Release Syndrome	01-17	MT
Poolbeg Pharma hails POLB 001'S potential to treat CRS	01-17	AN
Poolbeg Pharma plc Further Data Confirms Polb 001'S Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome	01-17	CI
K3 Business says cash balances ahead of forecast	12-20	AN
Poolbeg Pharma plc Announces Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV Drug Candidates with the High Probability of Successful Successful Successfully	12-20	CI
Poolbeg Pharma plc Announces Key Insights from Its Poster Presentation at ASH POLB 001	12-11	CI
Poolbeg Pharma plc Announces Directorate Changes	11-30	CI
Poolbeg hails approval; EDX links with Thermo Fisher	11-21	AN
Poolbeg Pharma appoints former Amryt executives to team	11-09	AN
Poolbeg Pharma Names Business, Legal Chiefs	11-09	MT
Poolbeg Pharma plc Announces Executive Appointments	11-09	CI
Poolbeg Pharma plc Announces Scientific Advisory Board Endorses Influenza Drug Targets Identified in Ai Drug Discovery Programme	23-10-26	CI

Chart Poolbeg Pharma PLC

Duration

Period

More charts

Company Profile

Poolbeg Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 001 Oncology, POLB 001 Influenza, AI Programs, Oral GLP-1R Agonist. Its POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer immunotherapy treatments which impacts 70% of patients undergoing CAR T or Bispecific Antibody therapy. The Company uses artificial intelligence to identify infectious disease drug targets & treatments. Its Oral GLP-1R Agonist is a delivery system which offers a scalable, natural, Generally Regarded As Safe (GRAS) approved solution for the oral delivery of metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes, obesity and other metabolic diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-06-02 - BIO International Convention

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.137 GBP

Average target price

0.21 GBP

Spread / Average Target

+53.28%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
POOLBEG PHARMA PLC	+51.38%	87.16M
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B
INSMED INCORPORATED	+77.64%	8.87B

Bio Therapeutic Drugs